Cbl-b-IN-29
Cbl-b-IN-29 is an orally active inhibitor of CBL-B. It effectively binds to the active site of CBL-B, thereby inhibiting the function of the immune E3 ubiquitin ligase. Cbl-b-IN-29 can induce the release of IL-2 from Jurkat cells with an EC50 of 159 nM. This compound exhibits significant antitumor efficacy in vivo, showing good tolerance with no adverse effects observed. Cbl-b-IN-29 is applicable in cancer immunotherapy and related studies involving colon cancer and tumor immunotherapy combinations.
Product Specifications
CAS Number
3070411-10-5
Smiles
CN1C ([C@@]2 (C[C@H] (C) C2) C3=CC (=CC=C3) C4=CC=5C (NC4=O) =C ([C@H] (NC6CCCC6) C) C=CC5F) =NN=C1
Molecular Formula
C30H34FN5O
Molecular Weight
499.63
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
More Discoveries
Explore Other Products
Browse additional items from our catalog
MBS6488288-01 0.1 mL
MRII, CT (Anti-Muellerian Hormone Type II Receptor, Anti-Muellerian Hormone Type II Receptor, AMH Type II Receptor, MIS Type II Receptor, MISRII, AMHR2, AMHR) (MaxLight 750)
Sign In for Pricing
View Details MBS6488288-02 5x 0.1 mL
MRII, CT (Anti-Muellerian Hormone Type II Receptor, Anti-Muellerian Hormone Type II Receptor, AMH Type II Receptor, MIS Type II Receptor, MISRII, AMHR2, AMHR) (MaxLight 750)
Sign In for Pricing
View Details K2750006 1.0 µg DNA
BTBD18 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 1)
Sign In for Pricing
View Details